Sign in
Taking people in NetherlandsPhase 1/2

T-Guard Safety Study for Early Diffuse Cutaneous Systemic Sclerosis

Tests T-Guard for safety in adults with early diffuse cutaneous systemic sclerosis.

Key facts

Who runs it
Philikos B.V.
Where
Nijmegen, NetherlandsSee the site
Registry title
T-Guard in dcSSc
Status
Recruiting
Phase
Phase 1/2
People taking part
13 people, planned
Started
29 Apr 2025
Expected to end
30 Jun 2027
Type of study
Interventional
Record updated
1 October 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults aged 18-75 with early diffuse cutaneous systemic sclerosis (a skin-hardening autoimmune disease) whose disease keeps getting worse despite earlier treatment.

Age
18 to 75 years
Sex
All sexes
Disease stage
Early diffuse cutaneous systemic sclerosis: skin involvement above and below the elbows and/or knees, disease duration of 36 months or less from the first non-Raynaud symptom, modified Rodnan skin score of 15 or more, and progressive skin or joint-and-muscle disease or lung disease (interstitial lung disease).
Earlier treatment
Must have failed at least one established immune-suppressing treatment (for example MTX, MMF, azathioprine, rituximab, tocilizumab, IVIG or cyclophosphamide), each tried for at least 3 months. Must have taken MTX or MMF for at least 3 months, at a stable dose for at least 8 weeks, and be willing to continue it. Other systemic treatments within 3 months before baseline are not allowed.

Main reasons for not taking part

  • Serious kidney problems, including creatinine of 2 mg/dL (177 µmol/L) or more or dialysis
  • Known active hepatitis B, C or E, or HIV or HTLV1 positive
  • Cancer within the past 5 years (except non-melanoma skin cancer or cervical cancer in situ)
  • Heart failure (LVEF below 45%) or signs of pulmonary hypertension unless right heart catheterization is normal
  • Moderate to severe restrictive lung disease, or continuous oxygen therapy

The registry criteria, word for word

Show all 27 criteriaShow less

Who can take part

  • Aged between 18-75 at the time of signing informed consent
  • With early dcSSc, defined as skin involvement above and below elbows and/or knees, disease duration ≤36 months from first non-Raynaud phenomenon
  • Modified Rodnan skin scores (MRSS) scores ≥15
  • Progressive skin or musculoskeletal (MKS)disease, e.g. worsening of skin with new areas of involvement or tendon friction rubs (TFR), with either Health Assessment Questionnaire Disability Index (HAQ-DI) >1.0 or elevated erythrocyte sedimentation rate (ESR)/C-reactive protein (CRP)
  • Interstitial lung disease (ILD) with forced vital capacity (FVC) 50-<80% predicted or lung diffusion testing (DLCO)(Hb corrected) 45-75% or >10% lung involvement on visual rad high-resolution computed tomography (HRCT) scan or those with progressive ILD, defined as progressive pulmonary fibrosis (PPF)-ILD in: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9851481/
  • Participants should have failed at least one established systemic immunosuppressive treatment for dcSSc (e.g., MTX, MMF , azathioprine, rituximab, tocilizumab, intravenous immunoglobulin [IVIG], or cyclophosphamide), each tried for at least 3 months, and: a. Have received treatment with MTX or MMF for at least 3 months prior to enrollment, with the dose stable for at least 8 weeks prior to enrollment; and b. Be able and willing, in the opinion of the investigator, to continue this background therapy at the stable dose throughout the study, unless dose reduction or discontinuation is clinically indicated due to adverse events
  • Participants should have given written informed consent

Who cannot take part

  • On continuous oxygen therapy
  • Known active infection with Hepatitis B, C, or E at screening (prior infections are not excluded), HIV or HTLV1 positivity
  • Participants who continue to receive any systemic treatment for systemic sclerosis, other than MTX or MMF, including but not limited to azathioprine, cyclosphosphamide, IVIG, rituximab, and tocilizumab, within three months prior to the baseline visit will be excluded. Continuation of oral corticosteroids (≤10 mg/day of prednisone or equivalent) and nonsteroidal anti-inflammatory drugs (NSAIDs) is permitted if the participant is on a stable dose for at least two weeks prior to and including the baseline visit
  • Latent infection with mycobacterium tuberculosis, unless history of treatment
  • Malignancy within the past 5 years, except for non-melanoma skin cancer or cervical cancer situ
  • Uncontrolled infection (infections are considered controlled if appropriate therapy has been instituted and, at the time of enrollment, no signs of progression are present) are not eligible for this trial
  • Known hypersensitivity to any of the components of murine monoclonal antibodies (mAb), or Recombinant Ricin Toxin A-chain (RTA)
  • Echocardiographic features consistent with pulmonary hypertension, unless right heart catheterization (RHC) is normal
  • Moderate to severe restrictive lung disease defined as FVC <50% predicted and/or DLCO Hb-corrected <45% predicted and presence of ILD on HRCT
  • Creatinine greater than or equal to 2mg/dL or creatinine clearance less than 60 mL/min or requiring hemodialysis. History or presence of glomerulonephritis, acute tubular necrosis, and/or interstitial nephritis or clinically significant findings as determined by urinalysis at screening
  • White blood cell count (WBC) <3000 µl
  • Platelets <100,000/mm3
  • Evidence of heart failure defined as left ventricular ejection fraction (LVEF) <45% as assessed by either echocardiography or multigated acquisition (MUGA) scan in the last 6 months
  • Albumin of less than or equal to 25 g/L
  • Creatine kinase (CK) level greater than 5 times the upper limit of normal (ULN)
  • Hemoglobulin (Hb) <9 g/dl
  • Significant gastrointestinal (GI) dysmotility requiring total parenteral nutrition or G or J tube
  • Vascular prosthesis
  • Need for mechanical ventilation and/or vasopressor support or requiring hemodialysis
  • Patients who have been diagnosed with scleroderma renal crisis (SRC) or another cause TMA anytime during their lifetime

Where in Netherlands

  • Radboud Universitair Medisch Centrum (Radboudumc)Nijmegen, NetherlandsTaking people

About the trial

What the trial wants to find out

To evaluate the safety of T-Guard in patients with early diffuse cutaneous systemic sclerosis (dcSSc), evaluated in all 13 study participants

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record

Print a page for my doctor

Saves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.

Data and sources

Registry record
Listed on the EU's official list of trials (CTIS).How to verify a trial in the registry
Official title
T-Guard against Autoreactive T cells in Systemic sclerosis: Erasion and Resolution (TASER)
Plain-language title
T-Guard Safety Study for Early Diffuse Cutaneous Systemic SclerosisGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 9 November 2026.
Record updated
1 October 2026